Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81‐8973 from rFVIII‐FS can continue their dosing schedule with improved protection

Detalles Bibliográficos
Autores principales: Solms, Alexander, Lalezari, Shadan, Shah, Anita, Kenet, Gili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383504/
https://www.ncbi.nlm.nih.gov/pubmed/32301248
http://dx.doi.org/10.1111/hae.13973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383504/
https://www.ncbi.nlm.nih.gov/pubmed/32301248
http://dx.doi.org/10.1111/hae.13973

Ejemplares similares